公开(公告)号：US20120277110A1

公开(公告)日：2012-11-01

申请号：US13386474

申请日：2010-07-26

申请人： Fabrice Andre ,  Ken André Olaussen ,  Jean-Charles Soria

发明人： Fabrice Andre ,  Ken André Olaussen ,  Jean-Charles Soria

IPC分类号： C40B30/04 ,  C40B40/10 ,  G01N33/573 ,  C40B40/06 ,  C12Q1/48 ,  C12Q1/68

CPC分类号： G01N33/57423 ,  G01N2333/91142 ,  G01N2800/52

摘要： The invention is generally directed to a diagnostic method for predicting the benefit of the response of a subject diagnosed with cancer to a platinum compound-based adjuvant chemotherapy, preferably to a cisplatin-based chemotherapy which implements the determination of the PARP expression level in the biological sample containing tumor cells, and, preferably, together with the MSH2 and/or ERCC1 expression level, more preferably together with the MSH2 and ERCC1 expression levels.

摘要翻译： 本发明一般涉及用于预测被诊断为癌症的受试者对基于铂化合物的辅助化疗的反应的益处的诊断方法，优选地以基于顺铂为基础的化学疗法，其实现了生物学中PARP表达水平的测定 含有肿瘤细胞的样品，优选与MSH2和/或ERCC1表达水平一起，更优选与MSH2和ERCC1表达水平一起。